# Gate2Brain

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gate2brain

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.gate2brain.com
- Total disclosed funding: $2.7M
- Latest round: Series D (Dec 21, 2022)
- Investors on record: 1

## About

Gate2Brain is a biotechnology company focused on innovative therapies to cross biological barriers, especially the blood-brain barrier, addressing critical needs in pediatric oncology.Gate2Brain specializes in developing therapeutics aimed at overcoming biological barriers, particularly for treating rare pediatric solid tumors. Founded by Esther Riambau, Gloria de Rozas, and Marc Castelltort, the company is headquartered in Barcelona, Spain. It raised EUR 2.5 million in its SERIES D funding round on December 21, 2022, led by EIC Accelerator, bringing the total amount raised to EUR 2.5 million.Gate2Brain (G2B) focuses on developing therapeutics that can effectively penetrate biological barriers, with G2B-002 being their primary product. This innovative treatment utilizes a peptide-based technology platform to enhance the efficacy of various therapeutic agents, targeting rare pediatric solid tumors. The company has received Orphan Drug Designation from the European Medicines Agency and the US FDA for G2B-002, indicating its commitment to addressing significant unmet medical needs within oncology and rare diseases. G2B aims to advance G2B-002 to Phase 1 clinical trials while working with healthcare providers and research institutions across the US and Europe.Gate2Brain's revenue structure is primarily based on partnerships and collaborations with pharmaceutical companies and research institutions. The company engages in licensing agreements and co-development partnerships to share risks and resources involved in the lengthy drug development process. While details on pricing for G2B-002 are not disclosed, pricing strategies are expected to consider developmental milestones, regulatory approvals, and market demand in the pediatric oncology sector. The latest reported EBITDA for 2023 is EUR -19,595.80.Gate2Brain plans to utilize the EUR 2.5 million raised in its recent funding round to facilitate the advancement of G2B-002 through clinical trials and explore further product development. The company aims to expand its reach within the pediatric oncology market in Europe and the United States, with a focus on bringing G2B-002 to market. Additionally, Gate2Brain is strategizing future product launches, although specific timelines have yet to be finalized.

## Funding rounds

- Series D, Dec 21, 2022, $2.7M — State Street Digital

## Investors

- State Street Digital (https://capitalatlas.ai/funds/state-street-digital) — Series D